These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

714 related items for PubMed ID: 29036231

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
    Apaijai N, Pintana H, Chattipakorn SC, Chattipakorn N.
    Br J Pharmacol; 2013 Jul; 169(5):1048-57. PubMed ID: 23488656
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin.
    Okajima F, Emoto N, Kato K, Sugihara H.
    J Atheroscler Thromb; 2017 Feb 01; 24(2):157-168. PubMed ID: 27397060
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
    Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR.
    Diabetologia; 2006 Sep 01; 49(9):2049-57. PubMed ID: 16816950
    [Abstract] [Full Text] [Related]

  • 54. Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels.
    Aoki K, Kamiyama H, Masuda K, Kamiko K, Noguchi Y, Tajima K, Terauchi Y.
    Endocr J; 2014 Sep 01; 61(3):249-56. PubMed ID: 24389993
    [Abstract] [Full Text] [Related]

  • 55. Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats.
    Murase H, Kuno A, Miki T, Tanno M, Yano T, Kouzu H, Ishikawa S, Tobisawa T, Ogasawara M, Nishizawa K, Miura T.
    Cardiovasc Diabetol; 2015 Aug 11; 14():103. PubMed ID: 26259714
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats.
    Eom YS, Gwon AR, Kwak KM, Kim JY, Yu SH, Lee S, Kim YS, Park IB, Kim KW, Lee K, Kim BJ.
    PLoS One; 2016 Aug 11; 11(12):e0168569. PubMed ID: 27997588
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.